TW202233178A - 固體配製物 - Google Patents

固體配製物 Download PDF

Info

Publication number
TW202233178A
TW202233178A TW110140905A TW110140905A TW202233178A TW 202233178 A TW202233178 A TW 202233178A TW 110140905 A TW110140905 A TW 110140905A TW 110140905 A TW110140905 A TW 110140905A TW 202233178 A TW202233178 A TW 202233178A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical formulation
formulation
api
pharmaceutical
hpmc
Prior art date
Application number
TW110140905A
Other languages
English (en)
Chinese (zh)
Inventor
棟華 朱
克里斯托佛 金普
蘇恩 安徒生
馬修 拉夫林根
伊萬 索默斯
Original Assignee
美商健生醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商健生醫藥公司 filed Critical 美商健生醫藥公司
Publication of TW202233178A publication Critical patent/TW202233178A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TW110140905A 2020-11-04 2021-11-03 固體配製物 TW202233178A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2020/126596 WO2022094816A1 (fr) 2020-11-04 2020-11-04 Formulation solide
WOPCT/CN2020/126596 2020-11-04

Publications (1)

Publication Number Publication Date
TW202233178A true TW202233178A (zh) 2022-09-01

Family

ID=78649077

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110140905A TW202233178A (zh) 2020-11-04 2021-11-03 固體配製物

Country Status (15)

Country Link
US (1) US20240000749A1 (fr)
EP (1) EP4240331A1 (fr)
JP (1) JP2023548348A (fr)
KR (1) KR20230104226A (fr)
CN (1) CN116685317A (fr)
AU (1) AU2021376584A1 (fr)
CA (1) CA3200538A1 (fr)
CO (1) CO2023005726A2 (fr)
CR (1) CR20230192A (fr)
DO (1) DOP2023000084A (fr)
MX (1) MX2023005219A (fr)
PE (1) PE20231946A1 (fr)
TW (1) TW202233178A (fr)
UY (1) UY39503A (fr)
WO (2) WO2022094816A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024080308A1 (fr) * 2022-10-12 2024-04-18 中外製薬株式会社 Composition contenant un peptide, un tensioactif et un polymère

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015103230A1 (fr) * 2013-12-31 2015-07-09 Ascendia Pharmaceuticals, Llc Compositions pharmaceutiques pour composés faiblement hydrosolubles
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3305289A1 (fr) * 2016-10-06 2018-04-11 Philipps-Universität Marburg Utilisation de silvestrol, épisilvestrol et silvestrol analoga pour le traitement d'infections virales provoquées par des virus avec traduction dépendante de la coiffe
KR102295179B1 (ko) * 2017-09-14 2021-08-30 피닉스 바이오테크놀러지 인코포레이티드. 바이러스 감염 치료를 위한 방법 및 조성물
US20190365738A1 (en) * 2018-05-21 2019-12-05 Cadila Healthcare Limited Amorphous solid dispersion of valbenazine tosylate and process for preparation thereof
AU2019344905A1 (en) * 2018-09-18 2021-04-29 Metacrine, Inc. Crystalline forms of a farnesoid X receptor agonist
KR102173092B1 (ko) * 2018-11-20 2020-11-02 중앙대학교 산학협력단 루테인 장용성 고체분산체를 유효성분으로 함유하는 위산보호용 조성물 및 이를 포함하는 경구용 제제
CN111407728B (zh) * 2020-04-16 2022-02-22 重庆市畜牧科学院 一种替米考星肠溶性固体分散体及其制备方法和应用

Also Published As

Publication number Publication date
JP2023548348A (ja) 2023-11-16
UY39503A (es) 2022-05-31
WO2022094816A1 (fr) 2022-05-12
AU2021376584A1 (en) 2023-06-29
DOP2023000084A (es) 2023-11-15
EP4240331A1 (fr) 2023-09-13
WO2022095913A1 (fr) 2022-05-12
CA3200538A1 (fr) 2022-05-12
CO2023005726A2 (es) 2023-05-29
US20240000749A1 (en) 2024-01-04
CR20230192A (es) 2023-10-26
KR20230104226A (ko) 2023-07-07
MX2023005219A (es) 2023-07-25
CN116685317A (zh) 2023-09-01
PE20231946A1 (es) 2023-12-05

Similar Documents

Publication Publication Date Title
US20030147950A1 (en) Modified release tamsulosin tablets
WO2008064202A2 (fr) Formulations à libération modifiée de composés actifs vis-à-vis du récepteur de calcium
EA027627B1 (ru) Фармацевтические препараты, содержащие антагонисты ccr3
US20140348909A1 (en) Pharmaceutical compositions of lurasidone
JP6168673B2 (ja) アリールアルキルアミン化合物含有医薬組成物
JP7346403B2 (ja) 難溶性の塩基性薬剤を含有する医薬組成物
US20220048900A1 (en) Amorphous sparsentan compositions
US11576917B2 (en) Pharmaceutical compositions comprising Ibrutinib
TW202233178A (zh) 固體配製物
US20170157095A1 (en) Allisartan isoproxil solid dispersion and pharmaceutical composition
CN114096530B (zh) 一种复合物的药物组合物及其制备方法
WO2012077968A2 (fr) Formulation complexe contenant de l'hydrochlorure de lercanidipine et du valsartan et son procédé de préparation
US20090030057A1 (en) Pharmaceutical composition of telmisartan
WO2022146007A1 (fr) Composition orale d'éfinaconazole
WO2020111089A1 (fr) Composition pharmaceutique
WO2022095912A1 (fr) Formulation pharmaceutique
TW202400144A (zh) 登革熱病毒感染之治療及／或預防
WO2022264004A1 (fr) Composition pharmaceutique comprenant de l'itraconazole
WO2019203746A2 (fr) Combinaison pharmaceutique comprenant du raloxifène et de l'aripiprazole
US20070004671A1 (en) Stable desloratadine compositions
TW202110444A (zh) 一種西達本胺藥物組合物及其製備方法和用途